[1] Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma. Retrieved December 18, 2019, from https://www.businesswire.com/news/home/20191218005788/en/
[2] Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma. Retrieved December 18, 2019, from http://www.epizyme.com/wp-content/uploads/2019/11/ICML_2019_FL_Morschhauser_105_oral-presentation_FINAL06212019.pdf
[3] Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma. Retrieved December 18, 2019, from https://www.businesswire.com/news/home/20191207005015/en/
